Amgen Inc (AMGN) Actualités

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND PR Newswire THOUSAND OAKS, Calif., Dec. 10, 2024 THOUSAND OAKS...

BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC...

Form 4 - Statement of changes in beneficial ownership of securities

AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA

AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA PR Newswire THOUSAND OAKS, Calif., Dec...

Form 4 - Statement of changes in beneficial ownership of securities

AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Dec. 2, 2024...

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE PR Newswire THOUSAND OAKS, Calif., Nov. 29...

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A...

AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM

AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM PR...

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT PR Newswire THOUSAND OAKS, Calif., Nov. 20, 2024 Howard...

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 PR Newswire THOUSAND OAKS, Calif., Nov...

MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM

MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM PR Newswire NEW YORK, Nov. 13, 2024 NEW YORK...

AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA

AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA PR Newswire THOUSAND OAKS, Calif., Nov. 13, 2024 THOUSAND...

AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif., Nov. 8, 2024...

TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS PR...